Journal of Cell Science and Therapy最新文献_第5页

An Unusual Condition Simulating Malignancy: A Patient with FibroepithelialPolyp of the Renal Pelvis Covered by the Blood Clot 模拟恶性肿瘤的异常情况:1例肾盂纤维上皮息肉被血凝块覆盖

Journal of Cell Science and Therapy Pub Date : 2016-02-10 DOI: 10.4172/2157-7013.1000237

C. Zhigang, J. Zhigang, Shi Bingbing, Huang Houfeng, Wang Qing-hai, F. Hua, Li Hanzhong

引用次数: 4

A View on Analytical Method Validation of Drugs 对药品分析方法验证的看法

Journal of Cell Science and Therapy Pub Date : 2016-02-09 DOI: 10.4172/2157-7013.1000235

Prakash Ch, A. Gupta

引用次数: 3

Latest Update on Pharmacological Activities of 1,3,4-Oxadiazole Derivatives 1,3,4-恶二唑衍生物药理活性的最新进展

Journal of Cell Science and Therapy Pub Date : 2016-02-09 DOI: 10.4172/2157-7013.1000233

B. Kumar, Arvind Kumar, A. Behera, V. Raj

引用次数: 15

Targeting Fibrosis in Pancreatic Ductal Adenocarcinoma: Emerging Role of Endothelial-to-Mesenchymal Transition 靶向纤维化在胰腺导管腺癌:内皮到间质转化的新作用

Journal of Cell Science and Therapy Pub Date : 2015-12-05 DOI: 10.4172/2157-7013.1000231

Pratiek N. Matkar, Hao-Hui Chen, Antoinette Bugyei-Twum, H. Leong-Poi, Krishna K Singh

{"title":"Targeting Fibrosis in Pancreatic Ductal Adenocarcinoma: Emerging Role of Endothelial-to-Mesenchymal Transition","authors":"Pratiek N. Matkar, Hao-Hui Chen, Antoinette Bugyei-Twum, H. Leong-Poi, Krishna K Singh","doi":"10.4172/2157-7013.1000231","DOIUrl":"https://doi.org/10.4172/2157-7013.1000231","url":null,"abstract":"Despite advances in our understanding of tumour biology and rapid strides in cancer therapies, malignant tumours remain a leading cause of morbidity and mortality [1-3]. Among these tumours, pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of mortality worldwide, with the lowest five-year survival rate [4-6]. Therefore, development of novel therapeutic strategies remains the urgent need of the hour. Poorly vascularized tumours like PDAC have remained largely untreatable despite the substantial innovations in anti-angiogenesis therapies [7,8]. At the morphological level, PDAC is characterized by an intense fibrotic reaction called tumour desmoplasia, primarily composed of the cancer-associated fibroblasts (CAFs) along with other stromal cells [9-12]. Recent findings have highlighted the crucial role of CAFs in numerous oncogenic events through alteration of the tumour microenvironment by releasing oncogenic as well as angiogenic factors [13-15]. Highly fibrotic PDAC tumours are often resistant to chemotherapy and radiation therapy due to high interstitial pressure and tumour microenvironment. This raised the question, “Could evolution of anti-fibrosis therapies treat PDAC?”","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122383552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Dual Role of Oligodendrocyte-Derived Myelin in Visual System Plasticity andRegeneration 少突胶质细胞来源髓磷脂在视觉系统可塑性和生成中的双重作用

Journal of Cell Science and Therapy Pub Date : 2015-11-18 DOI: 10.4172/2157-7013.1000228

H. R. Mendonça, S. Espírito-Santo, A. M. Martinez

引用次数: 1

Human METCAM/MUC18 as a Novel Biomarker to Drive and its Specific SiRNAs to Block the Malignant Progression of Prostate Cancer 人METCAM/MUC18作为驱动及其特异性sirna阻断前列腺癌恶性进展的新生物标志物

Journal of Cell Science and Therapy Pub Date : 2015-10-30 DOI: 10.4172/2157-7013.1000227

Guang-Jer Wu

{"title":"Human METCAM/MUC18 as a Novel Biomarker to Drive and its Specific SiRNAs to Block the Malignant Progression of Prostate Cancer","authors":"Guang-Jer Wu","doi":"10.4172/2157-7013.1000227","DOIUrl":"https://doi.org/10.4172/2157-7013.1000227","url":null,"abstract":"METCAM/MUC18, an integral membrane cell adhesion molecule (CAM) in the Ig-like gene superfamily, is capable of performing typical functions of CAMs, such as cell-cell and cell-extracellular interactions, crosstalk with intracellular signaling pathways, and modulating social behaviors. METCAM/MUC18 is not expressed in >90% of the epithelial cells of normal prostate, or in 100% of benign prostatic hyperplasia (BPH), but is expressed in >80% of prostatic intracellular neoplasia (PIN), high grade prostate cancers, and metastatic lesions. Its expression is also correlated with the malignant progression of mouse prostate adenocarcinoma in a transgenic model, TRAMP. Overexpression of human METCAM/MUC18 increases epithelial-to-mesenchymal transition (in vitro motility and in vitro invasiveness) of prostate cancer cells and in vivo tumorigenesis and metastasis to multiple organs after orthotopic injection of human prostatic cancer LNCaP cells in male nude mice. From our preliminary studies, it appears to regulate these processes via increasing proliferation, up-regulating the AKT-signaling pathway, increasing aerobic glycolysis, and augmenting angiogenesis of prostate cancer cells, but has no effect on apoptosis. Furthermore, soluble METCAM/MUC18 could block angiogenesis of LNCaP tumors and specific shRNAs in a lentivirus vector block tumorigenesis of DU145 cells in an athymic nude mouse model. Taken together, METCAM/MUC18 may be a useful novel biomarker for early diagnosis of the malignant potential of prostate cancer, but also a metastatic progression gene to drive the malignant progression of prostate cancer in a pre-clinic mouse model. METCAM/ MUC18-specific siRNAs and its derived oligo-peptides may be useful as therapeutic agents to block the malignant progression of the cancer.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"113 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114215386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Bronchogenic Cyst in the Liver Mimicking Metastasis of Colorectal Carcinoma: A Case Report and Review 模拟大肠癌转移的肝支气管囊肿1例报告及复习

Journal of Cell Science and Therapy Pub Date : 2015-10-30 DOI: 10.4172/2157-7013.1000225

M. Reichert, A. Hecker, Alex, er Brobeil, J. Holler, A. Amati, S. Gattenlöhner, J. Bodner, W. Padberg

{"title":"Bronchogenic Cyst in the Liver Mimicking Metastasis of Colorectal Carcinoma: A Case Report and Review","authors":"M. Reichert, A. Hecker, Alex, er Brobeil, J. Holler, A. Amati, S. Gattenlöhner, J. Bodner, W. Padberg","doi":"10.4172/2157-7013.1000225","DOIUrl":"https://doi.org/10.4172/2157-7013.1000225","url":null,"abstract":"Introduction: Carcinomas of the colon and rectum are the third most common cancer entity in the world and bear a high risk of synchronous (25%) or metachronous (50%) hepatic tumor seeding. For therapeutic decisions the differential diagnosis between benign and malignant hepatic lesions in the computer tomography scan is of major importance. We herein discuss congenital hepatic cysts derived from the primitive foregut as potential differential diagnosis for hepatic metastases from a colorectal primary tumor. \u0000Case presentation: A caucasian, 56-year old female patient with the initial diagnosis of an adenocarcinoma of the rectum had initially been treated by an anterior rectum resection and hemihepatectomy due to synchronous hepatic metastases (pT3 pN1(2/13), G2, pM1(HEP), L1, V0, pR0) in a curative intention. The follow-up staging after 2 years showed recurrent liver metastases. A local resection of the hepatic foci was performed. One of three lesions was classified as a classical ventral foregut derived bronchogenic cyst located subcapsularly in the liver. A follow-up resection of pulmonary metastases was performed 13 months later. The patient is still alive and healthy 68 months after the primary operation. \u0000Conclusions: For the diagnosis and treatment of hepatic metastases of colorectal carcinomas it is very useful to know potential differential diagnoses in radiographic imaging. Foregut derived cysts can be histologically subclassified into Ciliated Hepatic Foregut Cysts and Bronchogenic Cysts. While Ciliated Hepatic Foregut Cysts are known to be located in the liver, we present the rare case of a Bronchogenic Cyst, which was located in the liver parenchyma.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"155 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132372218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Challenges of Tuberculosis Treatment with DOTS: An Immune ImpairmentPerspective 直接督导下短程化疗治疗结核病的挑战:免疫损伤视角

Journal of Cell Science and Therapy Pub Date : 2015-10-28 DOI: 10.4172/2157-7013.1000223

Sultan Tousif, Shaheer Ahmad, Kuhulika Bhalla, P. Moodley, G. Das

{"title":"Challenges of Tuberculosis Treatment with DOTS: An Immune ImpairmentPerspective","authors":"Sultan Tousif, Shaheer Ahmad, Kuhulika Bhalla, P. Moodley, G. Das","doi":"10.4172/2157-7013.1000223","DOIUrl":"https://doi.org/10.4172/2157-7013.1000223","url":null,"abstract":"The World Health Organization (WHO) estimates that the causative agent of tuberculosis (TB) currently infects one third of the global population and is responsible for about 2 million deaths among those infected annually. Current therapy for TB consists of multiple expensive antibiotics (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol) and is lengthy, up to six months for drug-susceptible, and nine months or more for drug-resistant variants of TB. Although current TB treatment eradicates M.tb from the host body it also causes severe hepatotoxicity and other adverse side effects, causing a large number of patients to withdraw early from therapy. Additionally, displaying a phenomenon called therapy-related immune impairment; TB-treated patients are vulnerable to reactivation or reinfection of the disease. Once patients start feeling better, they often withdraw from treatment, especially those that live in resource-limited environments. Treatment withdrawal is largely responsible for the generation of drug-resistant variants of M.tb, including multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of M.tb. Therefore, new treatment approaches that reduce treatment regimen lengths and limit hepatotoxicity and other side effects are urgently needed.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132881830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Human Bio banking as a Team and a Networking project 人类生物银行作为一个团队和一个网络项目

Journal of Cell Science and Therapy Pub Date : 2015-10-10 DOI: 10.4172/2157-7013.E1000125

M. Marino, S. Canitano, G. Cigliana, E. Gallo, B. Antoniani, M. Chiara, oj, E. Pescarmona, M. Mottolese, L. Conti

{"title":"Human Bio banking as a Team and a Networking project","authors":"M. Marino, S. Canitano, G. Cigliana, E. Gallo, B. Antoniani, M. Chiara, oj, E. Pescarmona, M. Mottolese, L. Conti","doi":"10.4172/2157-7013.E1000125","DOIUrl":"https://doi.org/10.4172/2157-7013.E1000125","url":null,"abstract":"In medical research, human bio banking is directed to investigate the genetic, molecular and environmental factors underlying diseases. Population-based bio banking of blood from healthy individuals in large epidemiological cohorts and of biological fluids and tissue specimens both in healthy as well as in diseased subjects constitutes the \"core\" of biobanks. Population-based biobanks usually explore germline biological traits, whereas biobanks of specimens from diseased subjects aimed to investigate somatic alterations associated to different types of diseases. More in detail, several types of Bio banks exist: 1) Population bio banks, aimed to obtain biomarkers of identity and susceptibility, usually based on the DNA of a large cohort of healthy donor subjects, representative of an ethnic cohort; 2) Disease-oriented bio banks for epidemiology, based on a large sample number, aimed to identify biomarker exposure, usually following a healthy exposed cohort/case-control design. These biobanks study germline DNA or serum markers on the basis of large amounts of specifically designed and collected data; 3) Disease-oriented biobanks (usually tumor banks) aimed to identify disease biomarkers in a collections of samples and their derivates (DNA/RNA/proteins), usually associated to clinical data and / or clinical trials. The amount of clinical data linked to the sample determinates the availability and biological value of the sample. Biobank organization is a complex tool involving logistic infrastructures as well as specifically developed informatics tools and ethical issues.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114338992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Physical Therapy Interventions are Beyond Adjunct Care in ImprovingQuality of Life and Alleviating Pain Related to Cancer and its Treatment:Perspectives and Confronts 物理治疗干预在改善癌症及其治疗相关的生活质量和减轻疼痛方面超越辅助护理:观点和面对

Journal of Cell Science and Therapy Pub Date : 2015-10-09 DOI: 10.4172/2157-7013.1000229

J. Balamurugan, Ravich, ran Hariharasudhan

{"title":"Physical Therapy Interventions are Beyond Adjunct Care in ImprovingQuality of Life and Alleviating Pain Related to Cancer and its Treatment:Perspectives and Confronts","authors":"J. Balamurugan, Ravich, ran Hariharasudhan","doi":"10.4172/2157-7013.1000229","DOIUrl":"https://doi.org/10.4172/2157-7013.1000229","url":null,"abstract":"Cancer itself and evaluation, treatment procedures are associated with pain and impaired quality of life. Cancer pain relief is one the most difficult task for clinicians due to outsized barriers. Recent evidence suggests that patients with good control of symptoms related to cancer, including pain, helps patients live longer and the quality of life is also bettered at the same time. Analgesic ladder management of WHO is the most accepted and widely used pain management method in patients with cancer pain. But, use of opioids alone is not successful in pain control and improving quality of life. Exercise represents an effective therapeutic intervention for preparing patients to successfully complete treatments, for reducing acute, chronic and late side effects, and for improving QOL during and after treatments. This non systematic narrative review outlines the existing evidences of association between physical exercise, physical therapy intervention strategies, pain control and quality of life, evidence based exercise guidelines for cancer survivors and patients.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123993927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4